Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025)
Mesoblast (MESO) posted quarterly Non-Current Deffered Revenue of $2.5 million for Q4 2025, little changed year-on-year from $2.5 million in Q4 2024, and little changed on a QoQ basis from $2.5 million in Q2 2025.
Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Non-Current Deffered Revenue for 8 consecutive years, with $2.5 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue steadied at $2.5 million in Q4 2025 per MESO's latest filing, from $2.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for MESO reached as high as $2.5 million in Q1 2021 and fell as low as $2.5 million in Q1 2021.
- A 5-year average of $2.5 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
- Year by year, Non-Current Deffered Revenue stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Mar 31, 2020 | 2.50 Mn |
| Dec 31, 2019 | 10.00 Mn |